Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Q2 2019 Earnings Presentation
10 slides from Precigen's earnings presentation, Aug 8, 2019
Slide 1: Intrexon Second Quarter 2019 Business Update
Intrexon Second Quarter 2019 Business Update August 2019 Exhibit 99.2
Slide 2: Forward Looking Statements Safe Harbor Statement
Forward Looking Statements Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward
Slide 3: First Patients Dosed with Precigen's PRGN-3005 and PRGN-3006 UltraCAR-T Therapies
First Patients Dosed with Precigen’s Transformative PRGN-3005 and PRGN-3006 UltraCAR-T™ Therapies Status Phase1 study to evaluate safety and maximal tolerated dose is recruiting patients Study in collaboration with University of Washington and Fred Hutchinson Cancer Center Patient Population Advance
Slide 4: Precigen's Multigenic Candidate Exhibits Superior Anti-tumor Response
Precigen’s Multigenic Candidate Exhibits Superior Anti-tumor Response PRGN-5001 multifunctional therapeutic exhibits superior anti-tumor response compared to anti-PD1 in preclinical head and neck cancer model Humanized mouse model of head and neck cancer PRGN-5001 overcomes tumor microenvironment im
Slide 5: Triple-Gene Completes Cohort Dosing in Phase 1 Trial of INXN-4001
Triple-Gene Completes Cohort 1 Dosing in Phase 1 Clinical Trial of INXN-4001 to Target Heart Failure Triple-Gene LLC (formerly Xogenex LLC) is Intrexon’s majority owned subsidiary INXN-4001 is an investigational, non-viral, plasmid-based therapeutic candidate designed to drive expression of three ca
Slide 6: ActoBio Therapeutics Continues Clinical Progress on Microbe-based Delivery
ActoBio Therapeutics Continues Clinical Progress on Microbe-based Delivery of Biopharmaceuticals Initiated enrollment of next two patient cohorts of Phase Ib/IIa clinical trial for investigational drug AG019 for treatment of Type 1 Diabetes AG019 dosing in adolescents (patients 12-17 years of age) P
Slide 7: Okanagan Specialty Fruits (OSF) Expanding Market Plans
Okanagan Specialty Fruits (OSF) Expanding Market Plans Placed fresh sliced Arctic® apples in select markets, as well as dehydrated ApBitz™ apple snack on Amazon and in retail stores Planted 955,000 new Arctic® apple trees on 650 acres in Washington State, including first 80 acres of Arctic® Fujis, w
Slide 8: Oxitec 2nd Gen Friendly Aedes Advancing Pilot Programs
Oxitec 2nd Gen Friendly™ Aedes Advancing Pilot Programs Completed the first pilot project of its 2nd Generation Friendly™ Aedes aegypti technology in the city of Indaiatuba, Brazil Demonstrated the new strain’s effectiveness (treatment area compared to untreated control area) in suppressing populati
Slide 9: Operational Updates
Operational Updates Identification and implementation of significant operating cost reductions Concentrating focus on overall net cash and short-term investment position Transactions and Cost Savings: Prospective acquisition of Exemplar Genetics Considering offers for sale of Trans Ova Genetics Impl
Slide 10: “ntrexon
“ntrexon